文献速递肾移植

肾小球C4d免疫过氧化物酶在慢性抗体介导排斥反应与移植肾小球病中的应用

Glomerular C4d Immunoperoxidase in Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy.
PubMed 文献 · Kidney Int Rep · 2022-04-21

在3524例连续肾移植活检中评估肾小球毛细血管C4d(C4dglom)免疫过氧化物酶检测。C4dglom见于60.3%的移植肾小球病(TG),将其加入Banff慢性AMR诊断框架后,对电镜证实的TG诊断敏感性从22.2%升至82.4%,准确性从59.6%升至93.9%。作者推荐常规C4d免疫过氧化物酶检测以减少晚期AMR漏诊。

要点

  • C4dglom见于60.3%的移植肾小球病,正常肾小球中不表达。
  • 将C4dglom加入Banff慢性AMR框架可提高TG诊断敏感性和准确性。
  • 作者推荐常规C4d免疫过氧化物酶检测以减少晚期AMR漏诊。

核心结论

  • C4dglom是有前景的诊断生物标志物,反映内皮与抗体相互作用,可大幅提高Banff框架对TG的病理生理分类和移植肾失功预测能力。
  • 作者推荐常规C4d免疫过氧化物酶检测以减少TG中晚期AMR的漏诊。

研究设计与样本

  • 单中心连续纳入3524例肾移植活检,采用免疫过氧化物酶法评估C4d。
  • 对174例移植肾小球病(TG)进行分析,并以电镜(EM)验证TG诊断。

主要发现

  • C4dglom见于16.5%的活检,C4dptc见于9.9%的活检。
  • C4dglom见于60.3%的TG(n=174),正常肾小球中不表达。
  • 半定量C4dglom评分与供者特异性抗体(DSA)水平、C4dptc、微血管炎症(MVI)、Banff cg评分、肾功能不全和蛋白尿相关。
  • 多因素分析显示TG中DSA、C4dptc和移植后时间与C4dglom相关。
  • 将C4dglom加入Banff慢性AMR框架后,对EM验证的TG诊断敏感性从22.2%升至82.4%,准确性从59.6%升至93.9%(与仅用C4dptc的Banff 2019相比)。

关键数值与推荐

  • C4dglom在活检中的检出率为16.5%,C4dptc为9.9%。
  • C4dglom在TG中的检出率为60.3%(n=174)。
  • 加入C4dglom后Banff框架对TG诊断敏感性从22.2%升至82.4%,准确性从59.6%升至93.9%。
  • 组织C4dglom及纳入C4dglom的慢性AMR诊断与移植肾失功相关(P < 0.001)。

临床怎么用

  • 作者推荐常规C4d免疫过氧化物酶检测以减少TG中晚期AMR的漏诊。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The diagnosis of late antibody-mediated rejection (AMR) is compromised by frequent absence of C4d in peritubular capillaries (C4dptc), termed "C4d-negative" AMR. We hypothesized that glomerular capillary C4d (C4dglom) reflected endothelial interaction with antibody and could improve immunologic classification of transplant glomerulopathy (TG). METHODS: We evaluated C4d using immunoperoxidase in 3524 consecutive, kidney transplant biopsies from a single center. RESULTS: C4dglom was detected in 16.5% and C4dptc in 9.9% of biopsies. C4dglom occurred in 60.3% of TG (n = 174) and was absent in normal glomeruli. Epidemiologic risk factors for C4dglom were younger, female, living-donor recipients with early AMR, prior treated rejection, and late presentation using multivariable analysis. Semiquantitative C4dglom score correlated with donor specific antibody (DSA) level, C4dptc, microvascular inflammation (MVI), Banff cg scores, renal dysfunction, and proteinuria. Principal component analysis colocalized C4dglom with histologic AMR. Multivariable analysis of TG found DSA, C4dptc, and post-transplant time associated with C4dglom. Addition of C4dglom into Banff chronic AMR schema improved its diagnostic sensitivity for TG (verified by electron microscopy [EM]) from 22.2% to 82.4% and accuracy from 59.6% to 93.9%, compared with Banff 2019 using only C4dptc. Tissue C4dglom and chronic AMR diagnosis incorporating C4dglom were associated with death-censored allograft failure in TG (P < 0.001), independent of the severity of glomerulopathy and chronic interstitial fibrosis. CONCLUSION: C4dglom is a promising diagnostic biomarker of endothelial interaction with antibody which substantially improved test performance of the Banff schema to correctly classify TG by pathophysiology and prognosticate graft loss. We recommend routine C4d immunoperoxidase to minimize underdiagnosis of late AMR in TG.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Nankivell BJ, P'Ng CH, Shingde M, et al. Glomerular C4d Immunoperoxidase in Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy. Kidney Int Rep. 2022. PMID: 35812271. doi:10.1016/j.ekir.2022.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。